All In Biotech

Drug Trial Radar · NCT00160589

LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)

A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR)

Last checked: Nov 20, 2026Latest source record: Dec 16, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 729 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

729

Actual

Start

Apr 2005

Primary completion

Sep 2005

Study completion Sep 2005

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

  • LevocetirizineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline of T4SS (four symptoms score) over two weeks of treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.